Therapy of recurrent squamous cell carcinoma of the head and neck using combination vincristine, bleomycin, and methotrexate. A Southwest Oncology Group Study

Cancer. 1986 Dec 1;58(11):2382-5. doi: 10.1002/1097-0142(19861201)58:11<2382::aid-cncr2820581104>3.0.co;2-v.

Abstract

Fifty-six patients with squamous cell carcinoma of the head and neck were treated with the combination of vincristine, bleomycin, and methotrexate (VBM) on an every 2-week schedule. The overall CR + PR rate was 20%. Median response duration was 10 weeks. The toxicity during this trial was comparable to previously reported VBM regimens. The response rate was less than or no better than those previously reported for VBM or methotrexate alone. Therefore, this regimen offers nothing over methotrexate alone or other VBM regimens.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Actuarial Analysis
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / mortality
  • Drug Administration Schedule
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / mortality
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Vincristine
  • Methotrexate